Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer

Journal of Nuclear Medicine

Volumn 43, Issue 1, 2002, Pages 46-55

  Nuñez, Rodolfo ^a   Macapinlac, Homer A ^a   Yeung, Henry W D ^a   Akhurst, Tim ^a   Cai, Shangde ^a   Osman, Iman ^a   Gonen, Mithat ^a   Riedel, Elyn ^a   Scher, Howard I ^a   Larson, Steven M ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

11C methionine; 18F FDG; Bone scan; PET; Prostate cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; METHIONINE C 11; PROSTATE SPECIFIC ANTIGEN; CARBON; DIAGNOSTIC AGENT; METHIONINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; HISTOGRAM; HUMAN; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SOFT TISSUE; ADENOCARCINOMA; BONE TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; SCINTISCANNING; SOFT TISSUE TUMOR;

ADENOCARCINOMA; AGED; BONE NEOPLASMS; CARBON RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036007407     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Prostate cancer
2. Trends in prostate cancer in the United States, 1974-1990: Observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer
3. Bone metastases: Improving the therapeutic index
4. Hyperplasia and carcinoma of the prostate
5. Imaging techniques in cancer
6. Decrease in glucokinase and glucose-6-phosphatase and increase in hexokinase in putative preneoplastic lesions of the rat liver
7. 11C]methionine
8. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: Relationship between radioactivity uptake and flow cytometric parameters
9. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer
10. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study
11. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors
12. A new parameter for measuring metastatic bone involvement by prostate cancer: The bone scan index
13. Application of the McNemar test to non-independent matched pair data
14. The measurement of interrater agreement
15. The applications of PET in clinical oncology
16. 18F]fluorodeoxyglucose and positron emission tomography
17. Detection of bony metastases of androgen independent prostate cancer by FDG-PET
18. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose
19. C-11 methionine positron emission tomography in the management of prostatic carcinoma
20. C-11 methionine and F-18 PET imaging: Use in the evaluation of progressive prostate cancer
21. How much can we rely on the level of prostatespecific antigen as an end point for evaluation of clinical trials? A word of caution!
22. 18F]fluoro-2-deoxyglucose (FDG) in androgen independent prostate cancer
23. 18F PET
24. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
25. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
26. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
27. Positron emission tomography of a human prostate cancer xenograft: Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal